Axial Therapeutics Inc.
As the scientific leader in the biological role of the microbiome gut-brain axis and its impact on neurological conditions, Axial Therapeutics is uniquely positioned to advance a fundamentally different therapeutic approach for the treatment of neurological diseases and disorders. We stand apart through our focus on the microbiome, harnessing our expertise to identify new drug targets in the gut and develop novel medical interventions that have significant potential for improving symptoms and treating underlying disease.
At Axial, we are at the forefront of scientific innovation in the gut microbiome and its intersection with neurodegenerative diseases and neurodevelopmental disorders. We are dedicated to improving the lives of people with conditions such as Autism Spectrum Disorder and Parkinson’s disease by leveraging our understanding of the role of the microbiome and its impact on the nervous system.
Axial’s novel therapeutic approach is focused on the development of small molecule drugs with defined mechanisms of action that act on new targets in the gut to mitigate the impact of metabolites and bacteria linked to the pathology, progression, and symptoms of neurological diseases and disorders.
New Drug Targets. Bold Medical Interventions
Our focus on the microbiome gut-brain axis is a transformational shift from traditional approaches to treating neurological conditions. By identifying bacteria and their products in the gut that are linked to the pathology, progression, and symptoms of neurodegenerative diseases and neurodevelopmental disorders, we are able to validate “druggable” therapeutic targets in the gut microbiome. Based on these new classes of targets, we focus on developing small molecule therapies with defined mechanisms of action that mitigate the impact of bacteria and their products. Our localized, gut-targeted small molecule approach represents an evolution in microbiome-inspired therapeutics for neurological conditions.
Novel Medical Solutions for Patients with Autism and Parkinson’s Disease
Axial’s world-class expertise in microbiome gut-brain biology combines with the robust capabilities of our discovery platform to provide the foundation for our current and future pipeline of small molecule drugs for neurodegenerative diseases and neurodevelopmental disorders. Our lead programs are focused on the treatment of irritability in autism, and the slowing of disease progression in Parkinson’s disease. We are also leveraging our drug discovery platform to identify and validate druggable gut-resident targets for oncology indications.
Unique Expertise in Gut-Brain Biology, Small Molecule Development
Led by a capable management team that has extensive experience advancing small molecule therapies from discovery to commercialization, Axial is an industry leader in harnessing the gut-brain axis to treat disease and improve patients' lives.